Allergy Therapeutics plc (AIM: AGY), a UK-based biotechnology company that specialises in allergy vaccines, announced on Tueday that it has commenced subcutaneous dosing of peanut allergic patients in its Phase I/IIa PROTECT trial for the virus-like particle (VLP)-based peanut allergy vaccine candidate, VLP Peanut.
The trial, evaluating safety and efficacy, has observed no safety signals in skin-prick testing for peanut allergic patients in the Phase I stage. With incremental subcutaneous dosing initiated in both healthy volunteers and peanut allergic patients, the trial progresses to its double-blind, placebo-controlled Phase IIa stage for peanut allergic subjects in the US.
Conducted internationally, the PROTECT trial includes subcutaneous immunotherapy dosing in healthy volunteers and skin-prick testing in peanut allergic patients. The Phase IIa stage is expected to enroll up to 36 peanut-allergic subjects, contingent on dosing advancements.
EURneffy approved in EU for needle-free anaphylaxis treatment
Crossject secures EUR6.9m French government grant to advance ZENEO Epinephrine
Celltrion USA submits CT-P39 Biologics License Application to FDA
Ionis Pharmaceuticals names new executive vice president, chief global product strategy officer
Allergy Therapeutics reports positive G306 Phase III trial results for Grass MATA MPL
NeoImmuneTech's NT-I7 receives US FDA Orphan Drug Designation
Allergy Therapeutics reports positive interim results for G306 Phase III trial